GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (LSE:TCF) » Definitions » Net Change in Cash

TheraCryf (LSE:TCF) Net Change in Cash : £-3.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is TheraCryf Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

TheraCryf's Net Change in Cash for the six months ended in Mar. 2024 was £-1.72 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was £-3.00 Mil.


TheraCryf Net Change in Cash Historical Data

The historical data trend for TheraCryf's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf Net Change in Cash Chart

TheraCryf Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.10 1.46 -1.08 0.49 -3.00

TheraCryf Semi-Annual Data
Mar14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 -1.86 2.35 -1.27 -1.72

TheraCryf Net Change in Cash Calculation

TheraCryf's Net Change in Cash for the fiscal year that ended in Mar. 2024 is calculated as

TheraCryf's Net Change in Cash for the quarter that ended in Mar. 2024


Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-3.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TheraCryf Net Change in Cash Related Terms

Thank you for viewing the detailed overview of TheraCryf's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.


TheraCryf (LSE:TCF) Business Description

Traded in Other Exchanges
Address
Congleton Road, Suite 24G13- Block 24, Alderley Park, Nether Alderley, GBR, SK10 4TG
Evgen Pharma PLC is a UK-based clinical-stage drug development company. The company is focused on the development of sulforaphane-based compounds. Its core technology is Sulforadex, which synthesis and stabilizes the naturally occurring compound sulforaphane. Geographically, the company operates only in the United Kingdom. It is engaged in the treatment of breast cancer and Subarachnoid Haemorrhage.

TheraCryf (LSE:TCF) Headlines

From GuruFocus

TCF Financial Corp. CEO Craig R. Dahl to Retire

By Business Wire Business Wire 10-27-2020

Tcf Financial Corp (TCF) EVP, CFO Brian W Maass Sold $887,338 of Shares

By GuruFocus Research GuruFocus Editor 02-05-2021